Acurx Pharmaceuticals Statistics
Share Statistics
Acurx Pharmaceuticals has 22.4M
shares outstanding. The number of shares has increased by 39.31%
in one year.
| Shares Outstanding | 22.4M |
| Shares Change (YoY) | 39.31% |
| Shares Change (QoQ) | 30.49% |
| Owned by Institutions (%) | 8.62% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,745 |
| FTD / Avg. Volume | 0.69% |
Short Selling Information
The latest short interest is 418.92K, so 1.9% of the outstanding
shares have been sold short.
| Short Interest | 418.92K |
| Short % of Shares Out | 1.9% |
| Short % of Float | 2.15% |
| Short Ratio (days to cover) | 2.63 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.48 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.02 |
| P/FCF Ratio | -1.27 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Acurx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,525,775,750 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.09B |
| Effective Tax Rate | 99.9% |
Stock Price Statistics
The stock price has increased by -81.25% in the
last 52 weeks. The beta is -1.35, so Acurx Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -1.35 |
| 52-Week Price Change | -81.25% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 44.45 |
| Average Volume (20 Days) | 251,786 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -14.1B |
| EBITDA | -14.1M |
| EBIT | -14.1M |
| Earnings Per Share (EPS) | -872.54 |
Full Income StatementBalance Sheet
The company has 3.71M in cash and 0 in
debt, giving a net cash position of 3.71M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -67.32B |
| Total Assets | 3.86M |
| Working Capital | 615.12K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.38M
and capital expenditures 0, giving a free cash flow of -10.38M.
| Operating Cash Flow | -10.38M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.38M |
| FCF Per Share | -0.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
